Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Although DNA double-strand breaks (DSBs) are substrates for homologous recombination
(HR) repair, it is becoming apparent that DNA lesions produced at replication forks, for …

Abstract TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP) of bromo-
isophosphoramide mustard currently undergoing clinical evaluation. Here, we describe …

Chromosomal instability is a defining feature of clonal myeloma plasma cells that results in
the perpetual accumulation of genomic aberrations. In addition to its role in protein …

Purpose: The onset of drug resistance is a major cause of treatment failure in multiple
myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug …

Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …

Cancer initiating cells have been described to be the only cell population with tumorigenic
capacity in glioblastoma multiforme, one of the most aggressive and untreatable cancers …

It is widely believed that targeting the tumour-initiating cancer stem cell (CSC) component of
malignancy has great therapeutic potential, particularly in therapy-resistant disease …

Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-
producing plasma B cells. Proteasome inhibitors, including the US Food and Drug …

High heparanase expression is associated with enhanced tumor growth, angiogenesis, and
metastasis in many types of cancer. However, the mechanisms driving high heparanase …